The Government Told Women to Get Estrogen Patches. It Didn't Make Sure There Were Enough.
After reversing a 22-year-old warning on hormone therapy, the government did nothing to prepare the supply chain, and the shortage could last three years.
A 2002 study scared doctors away from hormone therapy for two decades.
Estrogen patches are cheap, hard to make, and no one built extra capacity.
Stopping estrogen suddenly brings the symptoms crashing back.
A 2002 study scared doctors away from hormone therapy for two decades.
The Women’s Health Initiative linked estrogen to heart disease, stroke, and breast cancer. Doctors stopped prescribing it for menopause symptoms like hot flashes, night sweats, and brain fog. Later research showed those risks had been overstated, especially for women under 60. But by then, an estimated 50 million women had gone without treatment or been talked out of it.
The FDA finally removed the black box warnings.
On November 10, 2025, HHS announced it would strip the bold safety warnings — called “black box” warnings — from hormone therapy products. By February 2026, new labels were approved for six products, with 29 more drug companies submitting changes.
Estrogen patch sales tripled in five years.
Women listened. Sales went from about 46.5 million units in 2020 to more than 142 million in 2025, according to IQVIA data reported by the Wall Street Journal. By February 2026, about 1 in 20 women aged 45 to 54 had a prescription for estrogen. But no one made sure there would be enough patches to go around.
Roughly 20 estrogen patch products are now in short supply.
Brands like Dotti and Lyllana are on back order with no clear return date. Others ship in small weekly batches. Some pharmacies have stock one day and nothing the next. The shortage could last up to three years. The FDA still has not declared an official national shortage, but some regions or suppliers are facing supply issues.
Estrogen patches are cheap, hard to make, and no one built extra capacity.
This is a math problem, not a factory breakdown. Patches need special materials and dedicated production lines. Manufacturers were already running at full speed. But margins on generic drugs are thin. No company invested in extra capacity, and new lines take years to build. Tariffs on overseas drug makers have added more pressure.
Stopping estrogen suddenly brings the symptoms crashing back.
Hot flashes, sleepless nights, brain fog can return quickly without treatment. Switching to a different brand or form of estrogen is possible, but you may need to get prior authorization from your insurance company for an alternative. Women with blood clot risks can’t safely switch to pills.
What doctors say to do right now.
Don’t stop on your own. Call other pharmacies, including your mail order pharmacy and independent pharmacies. Ask your doctor about a temporary switch. Refill early.
The FDA corrected one 22-year mistake. It just made a new one: telling millions of women to get a treatment, then leaving the supply chain to figure itself out.